NCT03154840Unknown1 期
A Randomized, Open Label, Single Subcutaneous Dose 6x3 Crossover Study to Investigate the Relative Bioavailability Among Different Eutropin Formulations in Healthy Male Volunteers
LG Chem1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2017年5月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- AUClast of somatropin
研究概览
简要总结
- Compares and evaluates the relative bioavailability of single-dose subcutaneous administration of each of the Eutropin formulations to healthy male volunteers.
- Ensure safety and tolerability of single, subcutaneous administration of Eutropin formulations to healthy male volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •A healthy male who is at least 19 years old but under 40 years of age at screening visit
- •Those who weigh more than 50 kg at screening visit and whose body mass index (BMI) is greater than 19 kg / m2 but less than 28 kg / m2
- •The result of the vital signs in the screening period.
- •A person who is judged to be clinically insignificant in terms of physical or mental condition when the examinee medically judges the screening period physical examination
- •Those who are not clinically significant when the examiner has medically judged the results of examination other than the items described in 17) and 18) of the exclusion criterion in the diagnosis laboratory test results in the screening period
- •A person who consents to use a combination of effective contraceptive methods or medically appropriate contraceptive methods from the first administration of the clinical trial drug to the fourth administration (28 days) after the last administration of the drug for clinical trial and not to provide sperm
- •Those who voluntarily decide to participate in clinical trials and observe the test subjects' precautions and agree in writing
排除标准
- •Those who with a history or history of diabetes
- •Those who with a history or history of malignancy
- •Those who with a history or history of musculoskeletal disorders (including epiphyseal closure, scoliosis, etc.)
- •Those who with history or history of endocrine system (including hypothyroidism, panhypopituitarism, etc.)
- •Those who have a history of skin disease, including psoriasis and contact dermatitis, or who can not exclude the possibility of skin disease under the judgment of the examiner on physical examination conducted at the screening visit.
- •Exclusion Criteria In addition to items 1) to 5), there are other clinically significant history or history of liver, kidney, digestive system, respiratory system, neuropsychiatry, blood /
- •Persons with a history of somatropin and octreotide acetate or hypersensitivity reactions to cresol, glycerol or other drugs (non-steroidal anti-inflammatory drugs, antibiotics, etc.)
- •Those who have participated in other clinical trials or bioequivalence tests within 90 days of the screening visit date
- •Within 60 days before screening visit Those who have received blood (blood, whole blood, etc.) or blood transfusions
- •Those who ingest herbal medicines or health functional foods within 14 days before the screening visit or those who are expected to affect the clinical trial within 7 days
- •Within 14 days prior to screening visit, special medicines that may affect the clinical trial, or those who use general medicines within 7 days
- •Screening Within 30 days prior to the visiting date Alcohol Abuse (alcohol-containing beverage> 21 units / week)
- •Over 30 days before screening visit Overcame smoker (cigarette> 10 cigarettes / day)
- •Within 7 days of screening visit Caffeine-containing foods Excessive intake (caffeinated foods> 3 times / week)
- •Screening Within 7 days prior to the visit Date of intake of food containing xanthine
- •As a result of urine nicotine test or urine drug screening test during the screening period
- •Screening period serum test (hepatitis B test, human immunodeficiency virus (HIV) test, hepatitis C test, syphilis test) Result positive
- •Diagnosis of Screening Period In the case of a laboratory test, one or more of the following findings
- •Fasting glucose> 110 mg / dL
- •TSH Reference Range Above upper limit or below lower limit
- •IGF-1 and IGFBP-3 according to the age of the test subjects. Reference range Above upper limit or below lower limit
- •Vitamin B12 Reference range above or below the upper limit
- •Insulin reference range above or below the upper limit
- •More than twice the AST or ALT or Alkaline Phosphatase (ALP) reference range upper limit
- •More than 1.5 times the upper limit of the bilirubin total reference range
- •A 12-electrode electrocardiogram in the screening period revealed a QTc> 450 ms or clinically significant abnormalities
- •Those who are judged to be inadequate to perform the clinical trial when the examiners judge them for other reasons
研究组 & 干预措施
Eutropin 4IU
Experimental
干预措施: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU (Drug)
Eutropin AQ 12IU
Experimental
干预措施: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU (Drug)
Eutropin Pen 36IU
Experimental
干预措施: Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU (Drug)
结局指标
主要结局
AUClast of somatropin
时间窗: Total three period at weekly intervals (Week 1, Week2, Week3)
Pharmacokinetic assessment
次要结局
- Peak Plasma Concentration (Cmax) of somatropin(Total three period at weekly intervals (Week 1, Week2, Week3))
- Area under the plasma concentration versus time curve (AUCinf) of somatropin(Total three period at weekly intervals (Week 1, Week2, Week3))
- Time at which the Cmax is observed (Tmax) of somatropin(Total three period at weekly intervals (Week 1, Week2, Week3))
- Elimination half-life time (t1/2β) of somatropin(Total three period at weekly intervals (Week 1, Week2, Week3))
- IGF-1(Total three period at weekly intervals (Week 1, Week2, Week3))
- IGF-BP3(Total three period at weekly intervals (Week 1, Week2, Week3))
- Monitoring of adverse reactions(Week -4(Screening), Week 1, Week 2, Week 3, Week 5)
- Physical examination(Week -4(Screening), Week 1, Week 2, Week 3, Week 5)
- Vital Signs(Week -4(Screening), Week 1, Week 2, Week 3, Week 5)
- Electrocardiogram(Week -4(Screening), Week 1, Week 2, Week 3, Week 5)
- Laboratory test(Week -4(Screening), Week 1, Week 2, Week 3, Week 5)
- Injection site reaction and Pain scale evaluation(Week 1, Week 2, Week 3)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fasting ConditionHealthyNCT01630655Torrent Pharmaceuticals Limited
已完成
1 期
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fed ConditionHealthyNCT01630902Torrent Pharmaceuticals Limited
已完成
1 期
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium 10mg Tablet Under Fasted ConditionsHealthyNCT01928056Torrent Pharmaceuticals Limited
已完成
1 期
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed ConditionsHealthyNCT01990586Torrent Pharmaceuticals Limited
已完成
1 期
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fed ConditionHealthyNCT01996501Torrent Pharmaceuticals Limited